By Andrew Black, Rare Disease Report
TapImmune announced the commencement of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200. TapImmune considers this a milestone in their research and development in helping cure triple negative breast cancer. TPIV 200 contains five peptide antigens freeze dried in a single vial, which is injected into the patient.
About Triple Negative Breast Cancer
Triple negative breast cancer is diagnosed when the 3 most common types of receptors known to fuel most breast cancer growth–estrogen, progesterone, and the HER-2/neu gene– are not present in the cancer tumor. Since the tumor cells lack the necessary receptors, common treatments like hormone therapy and drugs that target estrogen, progesterone, and HER-2 are ineffective.
Approximately 10-20% of breast cancers are found to be triple-negative and these are rare cancers that are in need of a better treatment.
Cancer Vaccine Clinical Trial
The clinical strategy for TPIV 200 is designed to examine the potential for the T-cell vaccine in as many clinical settings as possible using the most cost-effective pathways.
This Phase II trial evaluates the safety of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without an immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC)
Trials include monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence.
For more information about the clincial trial, click here